Meeting
2023 ASCO Annual Meeting
Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT).
Authors
Daniel Adam Breadner
Schulich School of Medicine and Dentistry, London, ON, Canada
Daniel Adam Breadner , Mark David Vincent , Geoffrey Liu , Jeffrey Rothenstein , Ines B. Menjak , Parneet Kaur Cheema , Rosalyn A. Juergens , Hamid Mithoowani , Puneet Bains , Ying Wang , Paul Wheatley-Price
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04335292
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS9160)
DOI
10.1200/JCO.2023.41.16_suppl.TPS9160
Abstract #
TPS9160
Poster Bd #
137b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.
First Author: Yuangyuan Zhao
Poster
2023 ASCO Annual Meeting
Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series.
First Author: Xiuning Le
Poster
2022 ASCO Annual Meeting
A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non–small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801).
First Author: Atsushi Nakamura
Poster
2021 ASCO Annual Meeting
Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).
First Author: Satoru Miura